Modern Management of Pregnancy Complicated
by Diabetes

Lois Jovanovic, MD

Module 1: Epidemiology of diabetes in women

Module 2: Diagnosis of type 2 diabetes during pregnancy

Module 3: Management of type 2 diabetes in pregnancy

Introduction

Lois Jovanovic, MD, CEO & Chief Scientific Officer,Sansum Diabetes Research Institute, discusses the management of type 2 diabetes during pregnancy. The risk of type 2 diabetes for pregnancy-related complications are reviewed and diagnosis and management recommendations are provided. Pre-pregnancy management of women with pre-existing diabetes is discussed.

Intended Audience

This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with type 2 diabetes.

Educational Objectives

After completing this activity, participants should be better able to:

Review the prevalence and shifting impact of diabetes in women of childbearing years
Describe the risk for pregnancy-related complications
Discuss diagnosis and screening recommendations
Identify the woman with type 2 diabetes
Discuss fetal origins of adult disease
Review pre-pregnancy management of women with pre-existing type 2 diabetes
Discuss diabetes management during pregnancy
Describe post-partum follow-up

Information on CME credit

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nonphysicians may receive a certificate of participation for completing this activity.

Instructions for CME credit

This online enduring material is presented as an audio webcast with attendant slide presentation. To receive credit, please view all of the presentations of this CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.

The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1.0 hour.

Principal Faculty

Lois Jovanovic, MD, FACE, Author/Presenter
CEO & Chief Scientific Officer
Sansum Diabetes Research Institute
Clinical Professor of Medicine
University of Southern California-Los Angeles Medical Center
Santa Barbara, CA

Stanley H. Hsia, MD, FRCPC, FACE, Planning Committee, Content Reviewer
Program Director, Endocrinology, Metabolism & Molecular Medicine
Assistant Professor of Medicine, Division of Endocrinology and Metabolism
Charles R. Drew University of Medicine and Science
UCLA School of Medicine
Los Angeles, CA

Daniel Einhorn, MD, FACP, FACE, Planning Committee, Content Reviewer
Medical Director, Scripps Whittier Institute for Diabetes
Clinical Professor of Medicine, UCSD
President, Diabetes and Endocrine Associates
La Jolla, CA

Martin S. Lipsky, MD, Planning Committee, Content Reviewer
Dean, University of Illinois College of Medicine at Rockford
Professor, Department of Family and Community Medicine
Rockford, IL

Col. Robert A. Vigersky, MD, Planning Committee, Content Reviewer
Director, Diabetes Institute
Walter Reed Health Care System
Clinical Associate Professor, Department of Medicine
Georgetown University School of Medicine
Washington, DC

R. Mark Evans, PhD, Planning Committee
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Kristi Eidsvoog, PhD, Planning Committee
Content Manager
MedEd Architects, LLC
Chicago, IL

Patti Fitzgerald, Planning Committee
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Disclosure Policy

In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.

These materials have been peer-reviewed by the members of the AMAprimarycare Diabetes Planning Committee to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final

Dr. Jovanovic: Nothing relevant to disclose

Dr. Lipsky: Nothing relevant to disclose

Dr. Hsia: Consultant, Merck

Dr. Einhorn: Research Grants, Aventis, Allergan, Lilly, Medtronic, Pfizer, sanofi-aventis; Consultant, Amylin, Lilly, MannKind, Medtronic, Takeda; Speaker’s Bureau, Amylin, Merck, sanofi-aventis, Takeda; Significant Shareholder, MannKind.

Dr. Vigersky: Research Grants, DexCom, NovoNordisk, Pfizer, Roche; Stockholder, Merck

Dr. Eidsvoog: Nothing relevant to disclose

Dr. Evans: Nothing relevant to disclose

Ms. Fitzgerald: Nothing relevant to disclose

Acknowledgement of Support

This CME publication was supported through an independent education grant from Takeda Pharmaceuticals and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.